Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 20 2025
0mins
Source: Yahoo Finance
Telix Pharmaceuticals Presentation at SNMMI 2025: Telix Pharmaceuticals will showcase five abstracts and two satellite symposia at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, focusing on their theranostic programs and products, including studies on prostate cancer and renal cancer imaging.
Commitment to Innovation in Cancer Care: Dr. David N. Cade emphasized Telix's dedication to advancing cancer treatment through innovative diagnostics and therapies, aiming to enhance clinical utility and patient outcomes in oncology.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
